The Role of Activator Protein-1 (AP-1) Family Members in CD30-Positive Lymphomas
Ines Garces de los Fayos Alonso 1,2,3,†, Huan-Chang Liang 3,†
, Suzanne D. Turner 4, Sabine Lagger 2,‡, Olaf Merkel 3,‡ and Lukas Kenner 1,2,3,*,‡
, Suzanne D. Turner 4, Sabine Lagger 2,‡, Olaf Merkel 3,‡ and Lukas Kenner 1,2,3,*,‡
1
Ludwig Boltzmann Institute for Cancer Research, 1090 Vienna, Austria
2
Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, 1210 Vienna, Austria
3
Clinical Institute of Pathology, Medical University of Vienna, 1090 Vienna, Austria
4
Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge CB21QP, UK
*
Author to whom correspondence should be addressed.
†
Co-first authors.
‡
Co-last authors.
Cancers 2018, 10(4), 93; https://doi.org/10.3390/cancers10040093
Received: 22 February 2018 / Revised: 21 March 2018 / Accepted: 25 March 2018 / Published: 28 March 2018
(This article belongs to the Special Issue Advances in Our Understanding of ALK-Related Cancers: A Selection of Papers from the Joint Annual Meeting of the European Research Initiative for ALK-Related Malignancies (ERIA) and the European Union Marie Curie European Training Network ALKATRAS)
Abstract
The Activator Protein-1 (AP-1) transcription factor (TF) family, composed of a variety of members including c-JUN, c-FOS and ATF, is involved in mediating many biological processes such as proliferation, differentiation and cell death. Since their discovery, the role of AP-1 TFs in cancer development has been extensively analysed. Multiple in vitro and in vivo studies have highlighted the complexity of these TFs, mainly due to their cell-type specific homo- or hetero-dimerization resulting in diverse transcriptional response profiles. However, as a result of the increasing knowledge of the role of AP-1 TFs in disease, these TFs are being recognized as promising therapeutic targets for various malignancies. In this review, we focus on the impact of deregulated expression of AP-1 TFs in CD30-positive lymphomas including Classical Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma. View Full-TextKeywords:
Activator Protein-1 (AP-1); Transcription Factors (TFs); Anaplastic Large Cell Lymphoma (ALCL); CD-30; Classical Hodgkin Lymphoma (CHL); Peripheral T-cell Lymphoma (PTCL)
▼
Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
Share & Cite This Article
MDPI and ACS Style
Garces de los Fayos Alonso, I.; Liang, H.-C.; Turner, S.D.; Lagger, S.; Merkel, O.; Kenner, L. The Role of Activator Protein-1 (AP-1) Family Members in CD30-Positive Lymphomas. Cancers 2018, 10, 93.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.